modelTalinolol
Extends from Pharmacolibrary.Drugs.ATC.C.C07AB13.
Information
| name: | Talinolol | |
| ATC code: | C07AB13 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 132 | mL/min |
| other parameters in model implementation | ||
Talinolol is a selective beta-1 adrenergic receptor blocker primarily used as an antihypertensive agent for the treatment of high blood pressure and certain types of cardiac arrhythmias. It is not widely used today as other beta-blockers are more commonly prescribed. Talinolol is approved in some countries but not universally.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, in oral dosing studies.
References
Fan, L, et al., & Zhou, HH (2009). Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. The Annals of pharmacotherapy 43(5) 944–949. DOI:10.1345/aph.1L656 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19401473
Sourgens, H, et al., & Derendorf, H (2003). Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. International journal of clinical pharmacology and therapeutics 41(1) 22–29. PUBMED:https://pubmed.ncbi.nlm.nih.gov/12564742
Weiss, M, et al., & Siegmund, W (2012). Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition. Journal of clinical pharmacology 52(3) 381–387. DOI:10.1177/0091270010396711 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21343347
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)